Cargando…

Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool

PURPOSE: Furosemide, a frequently prescribed diuretic for managing congestive heart failure and edema, remains a topic of debate regarding its potential risk of inducing acute kidney injury (AKI) in patients. Consequently, this study aims to examine the occurrence of hospital-acquired AKI (HA-AKI) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Chen, Li, Chenyu, Xu, Lingyu, Che, Lin, Wang, Yanfei, Yang, Chengyu, Zhang, Ningxin, Liu, Zengying, Zhao, Long, Zhou, Bin, Man, Xiaofei, Luan, Hong, Xu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474726/
https://www.ncbi.nlm.nih.gov/pubmed/37660080
http://dx.doi.org/10.1186/s40001-023-01306-0
_version_ 1785100564126760960
author Guan, Chen
Li, Chenyu
Xu, Lingyu
Che, Lin
Wang, Yanfei
Yang, Chengyu
Zhang, Ningxin
Liu, Zengying
Zhao, Long
Zhou, Bin
Man, Xiaofei
Luan, Hong
Xu, Yan
author_facet Guan, Chen
Li, Chenyu
Xu, Lingyu
Che, Lin
Wang, Yanfei
Yang, Chengyu
Zhang, Ningxin
Liu, Zengying
Zhao, Long
Zhou, Bin
Man, Xiaofei
Luan, Hong
Xu, Yan
author_sort Guan, Chen
collection PubMed
description PURPOSE: Furosemide, a frequently prescribed diuretic for managing congestive heart failure and edema, remains a topic of debate regarding its potential risk of inducing acute kidney injury (AKI) in patients. Consequently, this study aims to examine the occurrence of hospital-acquired AKI (HA-AKI) in hospitalized patients who are administered furosemide and to investigate potential risk factors associated with this outcome. METHODS: This study encompassed a cohort of 22374 hospitalized patients who either received furosemide treatment or not from June 1, 2012, to December 31, 2017. Propensity score matching was employed to establish comparability between the two groups regarding covariates. Subsequently, a nomogram was constructed to predict the probability of AKI occurrence among patients who underwent furosemide treatment. RESULTS: The regression analysis identified the single-day total dose of furosemide as the most significant factor for AKI, followed by ICU administration, estimated glomerular filtration rate, antibiotic, statin, NSAIDs, β-blockers, proton pump inhibitor, chronic kidney disease, and 7 other indicators. Subgroup analysis revealed a synergistic effect of furosemide with surgical operation, previous treatment with β-blockers, ACEI/ARB and antibiotics, leading to an increased risk of AKI when used in combination. Subsequently, a visually represented prognostic nomogram was developed to predict AKI occurrence in furosemide users. The predictive accuracy of the nomogram was assessed through calibration analyses, demonstrating an excellent agreement between the nomogram predictions and the actual likelihood of AKI, with a probability of 77.40%. CONCLUSIONS: Careful consideration of factors such as dosage, concurrent medication use, and renal function of the patient is necessary for clinical practice when using furosemide. Our practical prognostic model for HA-AKI associated with furosemide use can be utilized to assist clinicians in making informed decisions about patient care and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01306-0.Width
format Online
Article
Text
id pubmed-10474726
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104747262023-09-03 Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool Guan, Chen Li, Chenyu Xu, Lingyu Che, Lin Wang, Yanfei Yang, Chengyu Zhang, Ningxin Liu, Zengying Zhao, Long Zhou, Bin Man, Xiaofei Luan, Hong Xu, Yan Eur J Med Res Research PURPOSE: Furosemide, a frequently prescribed diuretic for managing congestive heart failure and edema, remains a topic of debate regarding its potential risk of inducing acute kidney injury (AKI) in patients. Consequently, this study aims to examine the occurrence of hospital-acquired AKI (HA-AKI) in hospitalized patients who are administered furosemide and to investigate potential risk factors associated with this outcome. METHODS: This study encompassed a cohort of 22374 hospitalized patients who either received furosemide treatment or not from June 1, 2012, to December 31, 2017. Propensity score matching was employed to establish comparability between the two groups regarding covariates. Subsequently, a nomogram was constructed to predict the probability of AKI occurrence among patients who underwent furosemide treatment. RESULTS: The regression analysis identified the single-day total dose of furosemide as the most significant factor for AKI, followed by ICU administration, estimated glomerular filtration rate, antibiotic, statin, NSAIDs, β-blockers, proton pump inhibitor, chronic kidney disease, and 7 other indicators. Subgroup analysis revealed a synergistic effect of furosemide with surgical operation, previous treatment with β-blockers, ACEI/ARB and antibiotics, leading to an increased risk of AKI when used in combination. Subsequently, a visually represented prognostic nomogram was developed to predict AKI occurrence in furosemide users. The predictive accuracy of the nomogram was assessed through calibration analyses, demonstrating an excellent agreement between the nomogram predictions and the actual likelihood of AKI, with a probability of 77.40%. CONCLUSIONS: Careful consideration of factors such as dosage, concurrent medication use, and renal function of the patient is necessary for clinical practice when using furosemide. Our practical prognostic model for HA-AKI associated with furosemide use can be utilized to assist clinicians in making informed decisions about patient care and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01306-0.Width BioMed Central 2023-09-02 /pmc/articles/PMC10474726/ /pubmed/37660080 http://dx.doi.org/10.1186/s40001-023-01306-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Guan, Chen
Li, Chenyu
Xu, Lingyu
Che, Lin
Wang, Yanfei
Yang, Chengyu
Zhang, Ningxin
Liu, Zengying
Zhao, Long
Zhou, Bin
Man, Xiaofei
Luan, Hong
Xu, Yan
Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title_full Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title_fullStr Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title_full_unstemmed Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title_short Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
title_sort hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474726/
https://www.ncbi.nlm.nih.gov/pubmed/37660080
http://dx.doi.org/10.1186/s40001-023-01306-0
work_keys_str_mv AT guanchen hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT lichenyu hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT xulingyu hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT chelin hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT wangyanfei hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT yangchengyu hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT zhangningxin hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT liuzengying hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT zhaolong hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT zhoubin hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT manxiaofei hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT luanhong hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool
AT xuyan hospitalizedpatientsreceivedfurosemideundergoingacutekidneyinjurytheriskandpredictiontool